Be the first to like this
Rising Drug Costs & Lack of New Treatments
As the U.S. deals with spiraling drug costs and an urgent need for new treatments, the Myelin Repair Foundation has pioneered a holistic approach to multiple sclerosis drug development that bridges the gap between the promising discoveries made in academic laboratories and big pharmaceutical drug research and development. The approach shows early promise in cutting development costs and shaving years off of the time it takes to develop a drug from basic science to patient therapy.
The Myelin Repair Foundation’s approach will not only benefit the millions living with MS but also provides a new source of high-quality drug targets for the dwindling biopharma pipelines.
Investing in Innovation
The Ewing Marion Kauffman Foundation, Pioneer Portfolio of the Robert Wood Johnson Foundation, and the Scott Cook & Signe Ostby Foundation are investing in MRF’s unique approach, its potential to accelerate the drug development process.
Online Webinar: March 25, 2010
All three organizations held a webinar on March 25, 2010 session to discuss why they support the MRF model and why attention should be paid to this new research paradigm.
Contact firstname.lastname@example.org with questions or media requests.